Abbott Labs Files 8-K on Financial Results & Operations

TL;DR

**Abbott Labs just dropped an 8-K with their latest financial results, so expect some market reaction.**

AI Summary

Abbott Laboratories filed an 8-K on January 24, 2024, to report its results of operations and financial condition, as well as related financial statements and exhibits. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it provides crucial, timely information about the company's health and future prospects, which can influence stock price and investment decisions.

Why It Matters

This filing provides investors with the latest financial performance data for Abbott Laboratories, which is essential for evaluating the company's health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently indicate high risk.

Analyst Insight

Investors should review the full financial statements and exhibits once available to understand the specifics of Abbott Laboratories' performance and adjust their investment thesis accordingly.

Key Numbers

• 001-02189 — Commission File Number (identifies Abbott Laboratories' registration with the SEC)
• 36-0698440 — IRS Employer Identification No. (identifies Abbott Laboratories for tax purposes)
• 224-667-6100 — Registrant's telephone number (contact information for Abbott Laboratories)

Key Players & Entities

• ABBOTT LABORATORIES (company) — the registrant filing the 8-K
• January 24, 2024 (date) — date of earliest event reported and filing date
• New York Stock Exchange (company) — exchange where ABT common shares are registered
• Chicago Stock Exchange, Inc. (company) — exchange where ABT common shares are registered
• ABT (company) — trading symbol for Abbott Laboratories

FAQ

Filing Documents

• abt-20240124.htm (8-K) — 28KB
• abt-2023q4xexhibitx991.htm (EX-99.1) — 853KB
• abbottlogo.jpg (GRAPHIC) — 7KB
• 0001628280-24-002009.txt ( ) — 1092KB
• abt-20240124.xsd (EX-101.SCH) — 2KB
• abt-20240124_def.xml (EX-101.DEF) — 15KB
• abt-20240124_lab.xml (EX-101.LAB) — 29KB
• abt-20240124_pre.xml (EX-101.PRE) — 16KB
• abt-20240124_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, charges for intangible asset impairments, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, tax benefit of certain intra-entity transfers of intellectual property, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated January 24, 2024 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: January 24, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Senior Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR